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Abstract
Alzheimer’s disease is a progressive irreversible neurodegenerative disorder, character-
ized by gradual decline of mental faculties including learning capacity, emotional and 
behavioral alterations, serious decline of motor skills, and dysfunction of the autonomic 
nervous system with disruption of circadian rhythms. Among the potential modifiable 
risk factors diabetes and obesity may play a considerable role in the pathogenetic back-
ground of the disease. We describe some of the morphological alterations of the hypotha-
lamic nuclei in early cases of Alzheimer’s disease, using silver impregnation techniques 
and electron microscopy. The morphological and morphometric study revealed substan-
tial decrease of the neuronal population, which was particularly marked in the suprachi-
asmatic, the supraoptic and the paraventricular nuclei of the hypothalamus. The silver 
staining demonstrated an obvious shortage of the dendritic arborization of neurons, asso-
ciated with marked spinal pathology and axonal dystrophy. It must be underlined that 
Alzheimer’s pathology, such as neuritic plaques and neurofibrillary degeneration was 
minimal in hypothalamus in comparison with other areas of the brain. Mitochondrial 
alterations and fragmentation of Golgi complex were observed by electron microscopy 
in a substantial number of neurons and astrocytes in the hypothalamic nuclei. The hypo-
thalamic pathology may be related to instability of autonomic regulation which occurs 
gradually in Alzheimer’s disease.
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1. Introduction
Alzheimer’s disease (AD) is a progressive devastating non reversible neurodegenerative 
disorder of the central nervous system, which has been recognized as the most common 
cause of serious cognitive decline in elderly people resulting in profound dementia [1, 2] 
with no effective therapy [3]. It is reasonable that AD induces a huge social burden and has 
a serious economic impact, since it starts frequently as mild cognitive impairment, resulting 
eventually in dementia, as the time advances [4, 5], affecting over 26 million people world-
wide [6, 7].
The pathogenesis of AD involves a considerable number of cellular and molecular underly-
ing mechanisms, as well as many genetic or acquired overlapping risk factors [8], such as 
diabetes, obesity and psychosocial stress, which although are among the modifiable factors, 
may contribute substantially in the rapid mental deterioration, aggravating the clinical phe-
nomenology of the disease [9].
A substantial number of clinical observations and laboratory investigations plead in favor of 
brain injury [8], stress [10–12], or stress-related psychiatric disorders [13, 14], type 2 diabetes 
[15, 16] insulin resistance [17, 18], inflammation [19] and depression [12, 20] as probable caus-
ative factors in the pathogenetic spectrum of AD [21].
The neuropathological profile of AD includes the formation of neuritic plaques, the neu-
rofibrillary degeneration in the form of tangles of highly phosphorylated tau proteins, the 
dendritic alterations, the spinal pathology, the marked alterations of dendritic spines, the 
dramatic reduce of the number of synapses, the substantial neuronal loss [22, 23], which is 
quite prominent mostly in limbic structures and selectively in various areas of the cortex 
of the brain hemispheres, as well as the phenomena of inflammation [24]. The prolonged 
gathering of the Aβ peptide in the brain activates microglial cells and pericytes reason-
ably, inducing neuroinflammation, which participates obviously in the ongoing pathogenic 
cascade of AD [24]. Coarse aggregations of Aβ amyloid peptide in the brain may conse-
quently promote degenerations of neurons and astrocytes, which are particularly sensitive 
in changes of protein homeostasis, energy decline and oxidative stress [25]. The vascular 
factor is an additional component of the pathogenetic cascade of AD, since the disruption 
of the BBB and the alterations of the brain capillaries [26, 27] could lead to infiltration of the 
perivascular space by immune cells, promoting reasonably the exacerbation of inflamma-
tory reactions [24].
The initial clinical manifestations of AD are subtle. However, as the time advances progres-
sive memory and learning impairment [28], language disturbances, visuospatial disorienta-
tion, ideomotor apraxia, behavioral disturbances, depressive symptoms [29–32], personality 
changes [33–35], and a multitude of non-cognitive symptoms, such as sleep disruption, circa-
dian dysrhythmia, changes in body weight and autonomic dysfunction progressively estab-
lish as principal dominant deficits in AD [36]. Sleep disturbances, on the other hand, might 
have a negative impact on the amyloid burden and the cognitive capacity of the patients, 
though the etiopathogenic mechanisms of the sporadic cases of AD remain yet unclear.
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Many hypotheses have been submitted concerning the various mechanisms of the pathoge-
netic process of AD, based mostly on the neuropathological investigation and the experi-
mental models of AD. Moreover the genetic investigation of the familial AD underline the 
heterogenetic character of AD, though the clinical investigation suggests that the disease at 
the advanced stages follows a common pathway with many other degenerative conditions of 
the brain [37, 38].
The oxidative stress correlated with the cortical and subcortical deposits of Aβ peptide can 
obviously play an important pathogenetic role in AD [39, 40]. In addition, the marked mito-
chondrial alterations in neurons and glial cells in cortical and subcortical structures and in cer-
ebellum [40, 41], which are mostly observed in dendrites deprived of spines, may contribute 
in shaping the pathogenetic pattern of the disease. On the other hand electron microscopy in 
early cases of AD revealed fragmentation of the cisternae of Golgi apparatus [42] even in areas 
where the characteristic Alzheimer’s pathology was unremarkable. The morphological altera-
tion of Golgi complex may be associated with the impairment of protein trafficking, acting as 
an additional pathogenetic component of AD. It is well recognized that Golgi complex is of 
instrumental importance in sorting and trafficking of the plasma proteins toward their final 
membranic target [43].
The autonomic nervous system participates in the brain dysfunction in case of AD either in 
the form of autonomic hyperactivity or of autonomic failure under the influence of strong 
exterior emotional inputs. The hypothalamus, the principal autonomic center is involved 
in advanced stages of AD [44–49], whereas the suprachiasmatic nucleus (SCN), which is 
the main circadian pacemaker, undergoes several continuous alterations during the course 
of the disease [50]. The activation of the hypothalamic-pituitary-adrenal (HPA) path-
way by exterior stimuli, inducing stress increase substantially the glucocorticoid release 
[49], which may modify the emotional and autonomic reactions of the patients who suffer 
from AD.
The modification of the volume of the third ventricle in AD may be considered as an evidence 
of the involvement of the hypothalamus, which would undergo pathological alterations in 
AD [51, 52], that may have a different molecular and cellular character in comparison with 
those observed in the hippocampus and in the cortex of the brain hemispheres [53], since 
hypothalamic plaques are not associated with increased gliosis or prominent disruption of 
the neuropile [53]. In addition the majority of diffuse plaques in the hypothalamus in case 
of AD may be labeled with an antiserum to the Aβ peptide, of the beta-amyloid precursor 
proteins (beta APPs), whereas Aβ peptide-immunoreactive plaques are rather uncommon in 
the hypothalamus of patients without AD [54]. It was also noticed that the neurofibrillary 
degeneration in the hypothalamus involves primarily those neurons that are associated with 
cortical areas which show prominent Alzheimer’s pathology [53].
Following our previous study [54] on the morphological alterations of the hypothalamus in 
AD, in this study we attempted to describe some additional morphological findings, con-
cerning the hypothalamic nuclei and the dendritic and spinal pathology in early cases of 
Alzheimer’s disease.
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2. Material and methods
2.1. Material
The morphological study of the hypothalamus concerns 14 autopsy cases of patients suffered 
from AD [54], at early stages according NINCDS-ADRDA criteria [55] and Braak and Braak 
staging [56] (Table 1). Twelve additional intact brains of apparently healthy individuals, who 
died accidentally, were used as normal controls [54].
Samples from the hypothalamus were excised and processed for electron microscopy and 
silver impregnation techniques including rapid Golgi’s method, Rio Hortega’s and Bodian’s 
techniques [57, 58].
2.2. Methods
2.2.1. Electron microscopy
For the electron microscopy the fixation of the specimens was performed in Sotelo’s fixing 
solution, according to method, which was described in previous article [54]. Then they were 
post-fixed in 1% osmium tetroxide, dehydrated in graded alcohol solutions and propylene 
oxide [54]. Thin sections were cut in a Reichert ultratome, contrasted with uranyl acetate and 
lead citrate and studied in a Zeiss 9aS electron microscope [54].
Gender Age at death Duration of the disease Length of brain fixation in months Braak and Braak stage
M 55 y 3 y 1 II/III
F 62 y 28 mo 1 II/III
M 63 y 37 mo 1 II
F 66 y 40 mo 1 II/III
M 72 y 3 y 1 III
M 74 y 38 mo 1 II/III
F 75 y 42 mo 1 II/III
F 76 y 46 mo 1 III
M 78 y 42 mo 1 II/III
F 80 y 2 y 1 II/III
M 78 y 42 mo 1 II/III
F 76 y 36 mo 1 III
M 54 y 2 y 1 III
M 65 y 37 mo 1 II/III
The hypothalamus was excised and studied from 1974 to 2011.
AD: Alzheimer’s disease, F: female, M: male. Fixation for silver impregnation techniques.
Table 1. List of the AD brains.
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2.2.2. Light microscope
2.2.2.1. Silver impregnation techniques
For the rapid Golgi staining, the hypothalamus, after 1 month’s fixation in fresh prepared 
formalin, was immersed in potassium dichromate for 10 days and in 1% silver nitrate for 
additional 10 days. Following dehydration in graded alcohol solutions, the specimens were 
embedded in paraffin and cut, some of them at 100 μ and some at 25 μ, alternatively [54]. 
Sections of 25 μ were stained also with methylene blue, according to Golgi-Nissl method 
[57–60]. All the sections were mounted in Entellan (Merck-Millipore, Darmstadt, Germany), 
between two cover slips and studied in a Zeiss Axiolab Photomicroscope, equipped with digi-
tal camera and computer.
We studied extensively the suprachiasmatic (SCN), the supraoptic (SON) and the paraven-
tricular nuclei (PVN) of the hypothalamus [45]. The volume of the nuclei was estimated 
according to Cavalieri principle [61, 62]. We described the type of dendritic arborization, the 
morphology of the dendritic branches and spines, and then we estimated the number of den-
dritic branches, as well as the spinal density, on sections stained according to rapid Golgi, and 
Golgi-Nissl methods.
2.2.3. Morphometry
Morphometric studies were performed with an image analyzer (Image J program). The mean 
surface area of the neurons, as well as the dendritic arborization, was calculated in silver 
staining [63]. The morphology of the soma and the dendrites was estimated on the basis of 
the criteria posed by Jacobs et al. [64], concerning the quality of staining of dendrites and the 
contrast between neurons and neuropile.
The estimation of the in space distribution of the dendritic branches was performed in a cen-
trifugal way according to Uylings et al. [65]. We estimated the diameter of the soma, the 
length of the dendrites, the number and the type of the dendritic branches, the length of 
dendritic segments per dendritic order and the spinal density per segment, given that each 
dendrite which arises from the neuronal body up to the first bifurcation is considered as first-
order dendritic branch.
For the quantitation we applied Image J program, which was properly adjusted for the used 
microscope (Carl Zeiss Axiolab Photomicroscope). The dendritic arborization was assessed 
on the basis of the method of concentric cycles introduced by Sholl [66].
The dendritic spines were counted on three sequent segments of the dendritic field. The first 
segment, 20–30 μm in length, was located on the primary dendrite, the second segment, 
20–30 μm in length, on the secondary one and the third segment of 40–50 μm, on the tertiary 
dendrite.
At the level of electron microscopy we applied the stereological estimation introduced by 
Nyengaard [67] and West [68–70]. We estimated the number, the length, the surface area, the 
volume and the spatial distribution for the mitochondria [54, 70] and for the cisternae and the 
vesicles of the Golgi complex [71].
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We estimated also the mean nuclear area, the dendritic profiles of the neurons [72], the spinal 
density per dendritic segment, the areas of the pre- and postsynaptic terminals [73–75] and 
the number of synaptic vesicles per presynaptic component [54, 75].
The statistical evaluation of the data was based on the Student t tests. P-values below 0.05 
were considered statistically significant, and those bellow 0.01, highly significant.
3. Results
3.1. Silver impregnation technique
From the anatomical point of view the human hypothalamus is extended from the level of 
lamina terminalis anteriorly to a level through the posterior commissure and the posterior edge 
of the mammillary bodies, posteriorly. Using the silver impregnation techniques, including 
Golgi-Nissl method, we could clearly visualize the neuronal population of the hypothalamic 
nuclei. We studied all the hypothalamic nuclei extensively; however we focused our descrip-
tion particularly on the suprachiasmatic (SCN), the supraoptic (SON) and the paraventricular 
nuclei (PVN).
In rapid Golgi method, the morphological and morphometric study of the neurons, demon-
strated a considerable decrease of the number of neurons, and a substantial loss of dendritic 
branches in the patients who suffered from AD (Figures 1 and 2), as compared with normal 
controls (Figures 3 and 4). Abbreviation of the dendritic arborization was prominent mostly 
in the neurons of suprachiasmatic nucleus (SCN) which was associated with marked decrease 
in the number of dendritic spines (Figures 5 and 6), in comparison with the normal control 
brains (Figure 7). The same morphological alterations concerning the dendritic branches and 
the spines were also observed in the supraoptic (SON) and paraventricular nuclei (PVN) of 
the hypothalamus in AD (Figure 8).
The morphometric estimation of the dendritic spines of the neurons of the SCN and SON 
revealed a dramatic decrease of their number in AD brains in comparison with normal con-
trols (Figure 9)
3.2. Electron microscopy
Detailed study on electron microscope revealed marked morphological changes of the neuro-
nal dendrites, which were prominent mostly in the secondary and tertiary dendritic branches 
of a considerable neuronal population of the suprachiasmatic (SCN), supraoptic (SON) and 
paraventricular nuclei (PVN) of the hypothalamus of patients who suffered from AD. Marked 
decrease in spine density was noticed in the dendritic branches of the neuronal networks of 
the hypothalamic nuclei, a phenomenon, which was particularly prominent in the suprachias-
matic nucleus. Small spines and giant spines were also observed in a considerable number of 
neurons of the suprachiasmatic nucleus. Many large and giant dendritic spines were observed, 
which included multivesicular bodies.
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Mitochondrial pathology was observed in many dendritic profiles in the suprachiasmatic and 
the paraventricular hypothalamic nuclei, of AD brains. The most frequent findings were the 
disruption of the cristae and the accumulation either fibrillary or osmiophilic material in the 
Figure 1. Neuron of the SCN nucleus in AD brain. Golgi staining 1200X.
Figure 2. Neuron of SCN of the hypothalamus in a case of AD. The loss of the dendritic branches is obvious. Golgi 
staining, magnification 1200×.
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mitochondria (Figure 8). The polymorphism of the mitochondria was also impressive, some 
of them being giant and very elongated and some being small and round.
The morphometric estimation of the mitochondria in the soma, the dendrites and the den-
dritic spines of a substantial number of neurons of the suprachiasmatic nucleus in AD brains 
Figure 3. Neuron of the SCN of the hypothalamus of a normal brain aged 75 years.
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Figure 4. Neuron of the SON of the hypothalamus of a normal brain aged 80 years. The dendritic branches have 
numerous spines. Golgi staining, magnification 1200×.
Figure 5. Abbreviation of the dendritic arborization is prominent in the neurons of suprachiasmatic nucleus (SCN) 
which is associated with marked decrease in the number of dendritic spines. Golgi staining, magnification 1200×.
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Figure 6. Neuron of the SCN of the hypothalamus of a case of AD. The abbreviation of the dendritic arborization and the 
poverty of dendritic spines is obvious. Golgi-Nissl staining, magnification 1200×.
Figure 7. Neuron of the SCN of the hypothalamus of a normal brain 80 years. The dendritic branches are covered by 
spines. Golgi staining, magnification 1200×.
revealed that they have an average diameter of 440 ± 250 nm and a mean axial ratio of 1.7 ± 
0.2. (Figure 10). In the same area the ellipsoid mitochondria of the dendritic spines of normal 
control brains have an average diameter of 650 ± 250 nm and a mean axial ratio of 1.9 ± 0.2., 
though the round mitochondria have a mean diameter of 350 nm. The mitochondrial cristae in 
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Figure 8. Mitochondrial alterations of a dendritic profile of a neuron of SCN of the hypothalamus of a case of AD. Electron 
micrograph, magnification 124,000×.
Figure 9. Average dendritic spines per dendritic arbor in SCN and SO neurons, based on measurements of 100 neurons 
(p < 0.005). AD: Alzheimer’s disease, NC: normal control, SCN: suprachiasmatic nucleus, SO: supraoptic nucleus.
Figure 10. Mean diameter (in nm) of mitochondria in neurons of suprachiasmatic nucleus, based on estimation of 500 
mitochondria (p < 0.05). AD, Alzheimer’s disease; NC, normal control.
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Figure 11. Alteration of Golgi apparatus of a neuron of the SCN nucleus of the hypothalamus of a case of AD. Electron 
micrograph, magnification 124,000×.
AD brains demonstrated serious changes such as disorientation, fragmentation and globular 
deformation. Mitochondrial alteration was also a frequent phenomenon in numerous astro-
cytes and pericytes in AD brains.
In a substantial number of neurons of the suprachiasmatic and paraventricular nuclei of the 
hypothalamus the Golgi apparatus appeared to be fragmented and atrophic (Figure 11). It 
was noticed that the atrophy or the fragmentation of Golgi apparatus (Figure 12) and the mito-
chondrial alterations coexisted with dendritic and spinal pathology in the majority of neurons.
Figure 12. The volume of Golgi apparatus in nm3. Based on measurements of 100 neurons of SCN (P < 0.005). AD, 
Alzheimer’s disease; NC: normal control, SCN, suprachiasmatic nucleus.
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4. Discussion
Hypothalamus is a crucial brain region for the regulation of substantial homeostatic func-
tions, including the circadian rhythms and the sleep–wake cycle. In Alzheimer’s disease and 
other neurodegenerative disorders [76–78] several hypothalamic nuclei are affected. It seems 
that the hypothalamic nuclei are not involved simultaneously at the early stages of AD. The 
suprachiasmatic nucleus seems to be more seriously affected than the others in aging [76]. In 
previous studies, it was clearly revealed that the total cell population in the suprachiasmatic 
nucleus is substantially decreased in aging and dramatically in AD [78] in which the hypotha-
lamic dysfunction is closely related to sleep disturbances [79].
The hypothalamic nuclei seem to be involved with various severities in the neurodegenera-
tive process, which progressively results in AD. In addition, the correlation of the alterations 
of the neuronal dendrites in the hypothalamic nuclei with those seen in the neocortex and the 
cerebellum, results in concluding that the hypothalamic alterations are modest in comparison 
with those, which are established in the acoustic area of the cortex, the visual cortex, the pre-
frontal areas and the cerebellar cortex [80–83].
The fact that the hypothalamus is the essential subcortical center of the homeostatic and auto-
nomic processes, may explain the reason why some nuclei such as the supraoptic and the 
periventricular ones reserve substantial synaptic density, even in the advanced stages of AD, 
in correlation with other subcortical and neocortical neurons,.
However, the suprachiasmatic nucleus demonstrated more severe dendritic alterations and 
synaptic loss than the supraoptic and paraventricular nuclei, a fact which might explain the 
phenomenon of desynchronization of circadian rhythms in the majority of the patients, who 
suffer from AD [84] or cognitive decline [85] in the spectrum of other degenerative conditions 
of the brain [86], given that suprachiasmatic nucleus is of crucial importance for the genera-
tion and synchronization of circadian rhythms in man [86, 87]. It is reported that changes of 
the circadian rhythm (CR), arterial blood pressure and circadian temperature may occur in 
AD patients [88], especially during the night time [89–91]. Changes also of the melatonin lev-
els are not an unusual phenomenon in advanced senility and AD [92–94]. Sundown syndrome 
on the other hand, frequently associated with increased motor activity is a rather common 
condition in advanced AD cases [95].
In a large number of neurons of the hypothalamic nuclei mitochondrial alterations were seen 
mostly in the soma and the dendrites. Mitochondria play an essential role in the energy sup-
ply of the cell, which is crucial in the alteration of reduction-oxidation potential of the cell, 
in the formation of free radicals, in scavenging activity, as well as in the intracellular cal-
cium control and the activation of apoptotic cascade [96–98]. Normally the mitochondria are 
numerous in the dendritic profiles and the axons, which have a continuous increased activ-
ity during the neuronal interactions. Mitochondrial density is also substantially high in the 
synaptic components, since mitochondria are the main energy generators for the ceaseless 
activity of the synapses.
Mitochondrial dysfunction may play an important role for enhancing the neurotoxic-
ity of the Aβ peptide, though increased mitochondrial proteostasis may reduce amyloid-β 
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proteotoxicity [99, 100]. In addition, impaired mitochondrial biogenesis contributes to mito-
chondrial dysfunction [101], which is directly associated with the oxidative stress, the main 
activator of the pathogenic cascade of AD [101–103].
Mitochondrial motility and accumulation are related to the functional state of the neuron, 
since mitochondria are transported to regions where necessity for energy is particularly high, 
as it occurs in the dendritic and axonal profiles and the synapses [103–105]. The shape and 
size of mitochondria are not stable, since they undergo continual fission and fusion which are 
necessary for cell survival and harmonious adaptation to changing conditions. Recent studies 
reported increased mitochondrial fission and decreased fusion, due to increased Aβ peptide 
interaction with the mitochondrial fission protein Drp 1, inducing increased mitochondrial 
fragmentation, impaired axonal transport of mitochondria and synaptic degeneration in 
AD [106, 107]. The consequence of the dynamic fusion and fission processes is the eventual 
mitophagy of the damaged mitochondria.
Nevertheless, a considerable diminution of the mitochondria is also seen in aging-related 
neurodegeneration [97, 98], as well as in the early stages of AD, when the mental decline 
is subtly detected [107]. In normal brains, few spines only contain small round mitochon-
dria in contrast to dendritic branches which mostly include large mitochondria that become 
numerous during synaptogenesis and in various conditions of hormonal disequilibrium 
[104, 106]. In AD, marked morphological changes of the mitochondria have been observed 
in neurons, which show an extensive loss of dendritic spines, associated with giant spines, 
distortion of spines and synaptic loss. The association of mitochondrial pathology with the 
synaptic loss is reasonably attributed to a sharp decrease of energy supply by the defected 
mitochondria [106, 108], a fact which occurs even at the initial stages of AD, when the typi-
cal Alzheimer pathology, consisted of the neuritic plaques and the neurofibrillary tangles is 
still minimal [109, 110].
The mitochondrial pathology, which is observed in the neurons of the hypothalamic nuclei 
are additional evidences of the causative role that mitochondrial dysfunction play in synaptic 
degeneration and loss of dendritic arbores in AD [111, 112]. In the suprachiasmatic nucleus of 
the hypothalamus a substantial number of neurons made evident the marked decrease of the 
spine density at the secondary and tertiary dendritic branches, which affects reasonably the 
neuronal interactions in AD. A substantial body of evidence plead also in favor of the impor-
tant role that mitochondria and Golgi complex play in the morphological and the quantitative 
stability of the dendritic spines in neuronal networks [105, 109–112], whereas experimental 
studies underline the spinal vulnerability to nonfibrillar Aβ peptide [110].
The hypothalamus play a central role in autonomic functions, including the generation and 
control of the circadian rhythms, the thermoregulation, the homeostasis of proteins [25], the 
maintenance of energy supply and the feeding behavior [113–115]. The pathological altera-
tions of hypothalamic nuclei in AD would induce the autonomic instability, which would be 
particularly prominent at the advanced stages of the disease, aggravating the clinical condi-
tion of the patients exceedingly [116–118], a fact which is also observed in experimental mod-
els of AD [119] as well as in the behavioral variant of frontotemporal dementia [120].
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In conclusion, the serious autonomic dysfunction in advanced stages of AD composes the 
tragic epilogue of the disease which is related with the involvement of the hypothalamus dur-
ing the continuous pathological process of the disease.
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